Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aurelius Health Group vs NextMeds

Aurelius Health Group
Graded #275

Lower grade

vs+3.799999999999997
NextMeds
Graded #208

Higher grade

The verdict

NextMeds takes it — 66.1/100 to 62.3/100.

NextMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NextMeds is a cash-pay telehealth platform offering compounded semaglutide and compounded tirzepatide on a flat monthly membership — one price bundling the medication (if prescribed), telehealth visits, a…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAurelius Health Group +5
60
55
Dose & formulationNextMeds +12
52
64
Clinical oversightNextMeds +1
76
77
Labs & monitoringAurelius Health Group +2
63
61
FulfillmentNextMeds +23
61
84
Contract termsEven
61
61
Aurelius Health Group · left barNextMeds · right bar

The numbers

MetricAurelius Health GroupNextMeds
WeighScore62.3/10066.1/100
GradeCC
Scorecard rank#275#208
SemaglutideNot disclosed$129/mo (plus a separate fee, compounded)
Tirzepatide$199/mo (microdose tier, compounded)$179/mo (plus a separate fee, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Aurelius Health Group

Graded #275 · C

Strengths

  • Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
  • LegitScript Certified
  • Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
  • Unusually candid about the limited evidence base for microdosing

Where it loses points

  • Microdose-only model — sub-therapeutic doses have thinner trial evidence and likely smaller weight loss than full-dose tirzepatide
  • No semaglutide or standard full-dose option
  • No named compounding pharmacy partner
  • No state list and no named medical director or pharmacist-in-charge
NextMeds

Graded #208 · C

Strengths

  • Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
  • Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
  • Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
  • Free, no-obligation online assessment before you pay anything

Where it loses points

  • Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
  • Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
  • A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard